← All trials
NCT05514002
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2022
- Primary completion
- Jun 15, 2024
- Completion date
- Sep 30, 2024
- First posted
- Aug 24, 2022
- Last posted
- Sep 16, 2022
- Enrollment
- 16247
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Centers for Disease Control and Prevention (CDC)Lead sponsor
- WestatCollaborator
- University of ArizonaCollaborator
- Baylor UniversityCollaborator
- University of UtahCollaborator
- Centers for Disease Control and Prevention (CDC)Overall official - principal investigator
- Centers for Disease Control and Prevention (CDC)Sponsor investigator
- CVS HealthCollaborator
- Florida A&M UniversityCollaborator
- Asian Health CoalitionCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.